IL317047A - Solid forms of heterocyclylamides as irak4 inhibitors - Google Patents

Solid forms of heterocyclylamides as irak4 inhibitors

Info

Publication number
IL317047A
IL317047A IL317047A IL31704724A IL317047A IL 317047 A IL317047 A IL 317047A IL 317047 A IL317047 A IL 317047A IL 31704724 A IL31704724 A IL 31704724A IL 317047 A IL317047 A IL 317047A
Authority
IL
Israel
Prior art keywords
heterocyclylamides
solid forms
irak4 inhibitors
irak4
inhibitors
Prior art date
Application number
IL317047A
Other languages
Hebrew (he)
Inventor
Okky Putra
Ina Terstiege
Anna Ingrid Kristina Berggren
Original Assignee
Astrazeneca Ab
Okky Putra
Ina Terstiege
Anna Ingrid Kristina Berggren
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab, Okky Putra, Ina Terstiege, Anna Ingrid Kristina Berggren filed Critical Astrazeneca Ab
Publication of IL317047A publication Critical patent/IL317047A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL317047A 2022-05-26 2023-05-25 Solid forms of heterocyclylamides as irak4 inhibitors IL317047A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263365387P 2022-05-26 2022-05-26
PCT/EP2023/064007 WO2023227703A1 (en) 2022-05-26 2023-05-25 Solid forms of heterocyclylamides as irak4 inhibitors

Publications (1)

Publication Number Publication Date
IL317047A true IL317047A (en) 2025-01-01

Family

ID=86692775

Family Applications (1)

Application Number Title Priority Date Filing Date
IL317047A IL317047A (en) 2022-05-26 2023-05-25 Solid forms of heterocyclylamides as irak4 inhibitors

Country Status (11)

Country Link
US (1) US20250326757A1 (en)
EP (1) EP4532499A1 (en)
JP (1) JP2025518579A (en)
KR (1) KR20250019656A (en)
CN (1) CN119137125A (en)
AU (1) AU2023274390A1 (en)
CA (1) CA3253370A1 (en)
CL (1) CL2024003580A1 (en)
IL (1) IL317047A (en)
MX (1) MX2024014493A (en)
WO (1) WO2023227703A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20250114A1 (en) 2021-06-03 2025-01-16 Chinook Therapeutics Inc SUBSTITUTED INDOL COMPOUNDS AND METHODS OF USING THEM

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3536685T3 (en) 2014-04-04 2022-05-16 Pfizer Inc. Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
WO2016174183A1 (en) 2015-04-30 2016-11-03 Bayer Pharma Aktiengesellschaft Combinations of inhibitors of irak4 with inhibitors of btk
EP3322409A4 (en) 2015-07-15 2019-07-24 Aurigene Discovery Technologies Limited AZA COMPOUNDS SUBSTITUTED AS INHIBITORS OF IRAQ-4
WO2017207386A1 (en) 2016-06-01 2017-12-07 Bayer Pharma Aktiengesellschaft Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases
CN110785418A (en) 2017-06-21 2020-02-11 豪夫迈·罗氏有限公司 Isoindolinone derivatives as IRAK4 modulators
US11866405B2 (en) * 2020-12-10 2024-01-09 Astrazeneca Ab Substituted indazoles as IRAK4 inhibitors

Also Published As

Publication number Publication date
JP2025518579A (en) 2025-06-17
EP4532499A1 (en) 2025-04-09
MX2024014493A (en) 2025-01-09
CL2024003580A1 (en) 2025-03-14
US20250326757A1 (en) 2025-10-23
KR20250019656A (en) 2025-02-10
CA3253370A1 (en) 2023-11-30
CN119137125A (en) 2024-12-13
WO2023227703A1 (en) 2023-11-30
AU2023274390A1 (en) 2025-01-02

Similar Documents

Publication Publication Date Title
HUE072981T2 (en) Azaquinolines as inhibitors of cd38
IL317736A (en) Compounds as inhibitors of axl
EP4263520A4 (en) Heterocyclic inhibitors of pcsk9
HUE068818T2 (en) Inhibitors of transglutaminases
IL304159A (en) Composition of bl-8040
HUE068724T2 (en) Inhibitors of transglutaminases
PL4192812T3 (en) Inhibitors of transglutaminases
IL326152A (en) Solid state forms of gusacitinib
IL314800A (en) Irak4 inhibitors
ES3065110T3 (en) Novel inhibitors of autotaxin
GB202203181D0 (en) Inhibitors of elF4A
GB202107612D0 (en) Inhibitors of metallo-beta-lactamases
IL326433A (en) Crystalline IRAK4 inhibitors
IL326153A (en) Solid state forms of gusacitinib
IL319179A (en) Solid state forms of denifanstat
IL317760A (en) Benzocarbazole derivatives as inhibitors of drp1
IL320661A (en) Solid forms of complement factor b inhibitors
CA3289184A1 (en) Heteroarylindole inhibitors of apol-1
HK40120257A (en) Irak4 inhibitors
HK40086963A (en) Inhibitors of sarm1
CA3280853A1 (en) Inhibitors of synaptogyrin-3 expression
HK40075448A (en) Inhibitors of sarm1
GB202211318D0 (en) Method of reducing nitro compounds
GB202311665D0 (en) Modification of composition
HK40121003A (en) Compounds as inhibitors of axl